Literature DB >> 9785295

Disease progression and cost of insulin dependent diabetes mellitus: development and application of a simulation model.

R H Tomar1, S Lee, S Y Wu, R Klein, B E Klein, S E Moss, D G Fryback, J L Tollios, F Sainfort.   

Abstract

This paper presents the development and application of a Markov model that simulates the onset and progression of insulin dependent diabetes mellitus (IDDM) and its sequelae. The model estimates direct medical costs resulting from different patterns of health states during the course of the disease. The model is user-friendly and allows for changes in the input variables to be specified, thereby providing a frame-work for sensitivity analysis. The Markov process moves a cohort of individuals through six different health states: Healthy, IDDM without chronic microvascular complications, IDDM with retinopathy alone, IDDM with neuropathy alone or with retinopathy, IDDM with nephropathy, and death. Epidemiologic data were obtained from governmental sources as well as the medical literature. Transition probabilities were estimated using data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR). Direct medical costs were estimated from actual charges from a local health maintenance organization in Wisconsin. The validity of the model was tested in several ways including a comparison with an independent cost estimate made by the Wisconsin Department of Health and Family Services. The model appears to be useful in estimating the progression and associated costs of IDDM for any large population over any period of time and in allowing changes in the inputs to evaluate their impact thus providing pertinent information to healthcare decision-makers and health planners.

Entities:  

Mesh:

Year:  1998        PMID: 9785295

Source DB:  PubMed          Journal:  J Soc Health Syst        ISSN: 1043-1721


  5 in total

1.  Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.

Authors:  Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Parmida Zarei; Aaron N Winn; Michael O'Grady; Elbert S Huang
Journal:  Med Decis Making       Date:  2018-11       Impact factor: 2.583

2.  Requisite models for strategic commissioning: the example of type 1 diabetes.

Authors:  Mara Airoldi; Gwyn Bevan; Alec Morton; Mónica Oliveira; Jenifer Smith
Journal:  Health Care Manag Sci       Date:  2008-06

3.  Simulating lifetime outcomes associated with complications for people with type 1 diabetes.

Authors:  Tom W C Lung; Philip M Clarke; Alison J Hayes; Richard J Stevens; Andrew Farmer
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

Review 4.  A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus.

Authors:  Martin Henriksson; Ramandeep Jindal; Catarina Sternhufvud; Klas Bergenheim; Elisabeth Sörstadius; Michael Willis
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

5.  Age-related alterations in retinal neurovascular and inflammatory transcripts.

Authors:  Colleen A Van Kirk; Heather D VanGuilder; Megan Young; Julie A Farley; William E Sonntag; Willard M Freeman
Journal:  Mol Vis       Date:  2011-05-07       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.